The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts

Seminars in Cancer Biology

Volumn 21, Issue 2, 2011, Pages 139-146

  Peinado, Héctor ^a,b   Lavotshkin, Simon ^a,b,c   Lyden, David ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Champalimaud Metastasis Programme   (Portugal)

^c MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Bone marrow progenitor cells; Bone marrow derived cells; Exosomes; Metastasis; Microvesicles; Pre metastatic niche; Tumor

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; CALGRANULIN A; CD11B ANTIGEN; CD133 ANTIGEN; CD14 ANTIGEN; CD44V6 ANTIGEN; FIBRONECTIN; GELATINASE B; PROTEIN LYSINE 6 OXIDASE; PROTEIN S 100; PROTEIN S 100A9; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VERY LATE ACTIVATION ANTIGEN 4;

CELL COMMUNICATION; CELL VACUOLE; COEVOLUTION; COLORECTAL CANCER; CYTOKINE RELEASE; DENDRITIC CELL; EXOSOME; HEMATOPOIETIC STEM CELL; HUMAN; INFLAMMATION; LIVER METASTASIS; MALIGNANT TRANSFORMATION; MEMBRANE VESICLE; METASTASIS; MICROMETASTASIS; MICROVESICLE; NONHUMAN; POSITIVE FEEDBACK; PREMETASTATIC NICHE FORMATION; REVIEW; SHEDDING VESICLE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANIMALS; BONE MARROW CELLS; CELL COMMUNICATION; CYTOPLASMIC VESICLES; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 79952070774     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.01.002     Document Type: Review

References (88)

1. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9(4):239-252.
2. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer 2009, 9(4):274-284.
3. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989, 8(2):98-101.
4. Poste G., Fidler I.J. The pathogenesis of cancer metastasis. Nature 1980, 283(5743):139-146.
5. Fidler I.J., Yano S., Zhang R.D., Fujimaki T., Bucana C.D. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002, 3(1):53-57.
6. Fidler I.J. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg. Oncol. Clin. N. Am. 2001, 10(2):257-269. vii-vii10.
7. Psaila B., Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 2009, 9(4):285-293.
8. Wels J., Kaplan R.N., Rafii S., Lyden D. Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev. 2008, 22(5):559-574.
9. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005, 438(7069):820-827.
10. Hiratsuka S., Nakamura K., Iwai S., Murakami M., Itoh T., Kijima H., et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002, 2(4):289-300.
11. Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 2006, 8(12):1369-1375.
12. Hiratsuka S., Watanabe A., Sakurai Y., Akashi-Takamura S., Ishibashi S., Miyake K., et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol. 2008, 10(11):1349-1355.
13. Arai K., Takano S., Teratani T., Ito Y., Yamada T., Nozawa R. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr. Cancer Drug Targets 2008, 8(4):243-252.
14. Peinado H., Rafii S., Lyden D. Inflammation joins the " niche" Cancer Cell 2008, 14(5):347-349.
15. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 2004, 4(7):540-550.
16. Solinas G., Marchesi F., Garlanda C., Mantovani A., Allavena P. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev. 2010, 29(2):243-248.
17. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15(1):35-44.
18. Fogelgren B., Polgar N., Szauter K.M., Ujfaludi Z., Laczko R., Fong K.S., et al. Cellular fibronectin binds to lysyl oxidase with high affinity and is critical for its proteolytic activation. J. Biol. Chem. 2005, 280(26):24690-24697.
19. Xiang X., Poliakov A., Liu C., Liu Y., Deng Z.B., Wang J., et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer 2009, 124(11):2621-2633.
20. Ye X.Z., Yu S.C., Bian X.W. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis. J Genet Genomics 2010, 37(7):423-430.
21. Cheng P., Corzo C.A., Luetteke N., Yu B., Nagaraj S., Bui M.M., et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 2008, 205(10):2235-2249.
22. Bhowmick N.A., Moses H.L. Tumor-stroma interactions. Curr. Opin. Genet. Dev. 2005, 15(1):97-101.
23. Hu M., Polyak K. Molecular characterisation of the tumour microenvironment in breast cancer. Eur. J. Cancer 2008, 44(18):2760-2765.
24. Gao D., Mittal V. The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. Trends Mol. Med. 2009, 15(8):333-343.
25. Gao D., Nolan D., McDonnell K., Vahdat L., Benezra R., Altorki N., et al. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim. Biophys. Acta 2009, 1796(1):33-40.
26. Gao D., Nolan D.J., Mellick A.S., Bambino K., McDonnell K., Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008, 319(5860):195-198.
27. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7(11):1194-1201.
28. Li H., Gerald W.L., Benezra R. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res. 2004, 64(17):6137-6143.
29. Mellick A.S., Plummer P.N., Nolan D.J., Gao D., Bambino K., Hahn M., et al. Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth. Cancer Res. 2010, 70(18):7273-7282.
30. Taylor M., Rossler J., Geoerger B., Laplanche A., Hartmann O., Vassal G., et al. High levels of circulating VEGFR2+ Bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin. Cancer Res. 2009, 15(14):4561-4571.
31. Naik R.P., Jin D., Chuang E., Gold E.G., Tousimis E.A., Moore A.L., et al. Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer. Breast Cancer Res. Treat. 2008, 107(1):133-138.
32. Su Y., Zheng L., Wang Q., Li W., Cai Z., Xiong S., et al. Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer. J. Exp. Clin. Cancer Res. 2010, 29:27.
33. Greenfield J.P., Jin D.K., Young L.M., Christos P.J., Abrey L., Rafii S., et al. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery 2009, 64(5):819-826. discussion 826-827.
34. Bogos K., Renyi-Vamos F., Dobos J., Kenessey I., Tovari J., Timar J., et al. High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin. Cancer Res. 2009, 15(5):1741-1746.
35. Ronzoni M., Manzoni M., Mariucci S., Loupakis F., Brugnatelli S., Bencardino K., et al. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann. Oncol. 2010.
36. Yamamoto M., Kikuchi H., Ohta M., Kawabata T., Hiramatsu Y., Kondo K., et al. TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res. 2008, 68(23):9754-9762.
37. De Palma M., Murdoch C., Venneri M.A., Naldini L., Lewis C.E. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol. 2007, 28(12):519-524.
38. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8(3):211-226.
39. Spring H., Schuler T., Arnold B., Hammerling G.J., Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci USA 2005, 102(50):18111-18116.
40. Coffelt S.B., Tal A.O., Scholz A., De Palma M., Patel S., Urbich C., et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res. 2010, 70(13):5270-5280.
41. Figueroa-Vega N., Diaz A., Adrados M., Alvarez-Escola C., Paniagua A., Aragones J., et al. The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors. Endocr Relat Cancer 2010, 17(4):897-908.
42. Takakura N., Watanabe T., Suenobu S., Yamada Y., Noda T., Ito Y., et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000, 102(2):199-209.
43. Bae D.G., Kim T.D., Li G., Yoon W.H., Chae C.B. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clin. Cancer Res. 2005, 11(7):2651-2661.
44. Kaplan R.N., Rafii S., Lyden D. Preparing the " soil": the premetastatic niche. Cancer Res. 2006, 66(23):11089-11093.
45. Ratajczak J., Wysoczynski M., Hayek F., Janowska-Wieczorek A., Ratajczak M.Z. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006, 20(9):1487-1495.
46. Cocucci E., Racchetti G., Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009, 19(2):43-51.
47. Thery C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2(8):569-579.
48. Fevrier B., Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr. Opin. Cell Biol. 2004, 16(4):415-421.
49. Muralidharan-Chari V., Clancy J.W., Sedgwick A., D'Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J. Cell Sci. 2010, 123(Pt 10):1603-1611.
50. Andre F., Schartz N.E., Movassagh M., Flament C., Pautier P., Morice P., et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002, 360(9329):295-305.
51. Chaput N., Schartz N.E., Andre F., Taieb J., Novault S., Bonnaventure P., et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J. Immunol. 2004, 172(4):2137-2146.
52. Chaput N., Schartz N.E., Andre F., Zitvogel L. Exosomes for immunotherapy of cancer. Adv. Exp. Med. Biol. 2003, 532:215-221.
53. Valenti R., Huber V., Iero M., Filipazzi P., Parmiani G., Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007, 67(7):2912-2915.
54. van Niel G., Porto-Carreiro I., Simoes S., Raposo G. Exosomes: a common pathway for a specialized function. J. Biochem. 2006, 140(1):13-21.
55. Ratajczak J., Miekus K., Kucia M., Zhang J., Reca R., Dvorak P., et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006, 20(5):847-856.
56. Baj-Krzyworzeka M., Szatanek R., Weglarczyk K., Baran J., Urbanowicz B., Branski P., et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol. Immunother. 2006, 55(7):808-818.
57. Lakkaraju A., Rodriguez-Boulan E. Itinerant exosomes: emerging roles in cell and tissue polarity. Trends Cell Biol. 2008, 18(5):199-209.
58. Iero M., Valenti R., Huber V., Filipazzi P., Parmiani G., Fais S., et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008, 15(1):80-88.
59. Liu Y., Xiang X., Zhuang X., Zhang S., Liu C., Cheng Z., et al. Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am. J. Pathol. 2010, 176(5):2490-2499.
60. Yu S., Liu C., Su K., Wang J., Liu Y., Zhang L., et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 2007, 178(11):6867-6875.
61. Janowska-Wieczorek A., Wysoczynski M., Kijowski J., Marquez-Curtis L., Machalinski B., Ratajczak J., et al. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int. J. Cancer 2005, 113(5):752-760.
62. Janowska-Wieczorek A., Majka M., Kijowski J., Baj-Krzyworzeka M., Reca R., Turner A.R., et al. Platelet-derived microparticles bind to hematopoietic stem/progenitor cells and enhance their engraftment. Blood 2001, 98(10):3143-3149.
63. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9(6):654-659.
64. Valenti R., Huber V., Filipazzi P., Pilla L., Sovena G., Villa A., et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006, 66(18):9290-9298.
65. Janowska-Wieczorek A., Marquez-Curtis L.A., Wysoczynski M., Ratajczak M.Z. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion (Paris) 2006, 46(7):1199-1209.
66. Nazarenko I., Rana S., Baumann A., McAlear J., Hellwig A., Trendelenburg M., et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 2010, 70(4):1668-1678.
67. Aliotta J.M., Pereira M., Johnson K.W., de Paz N., Dooner M.S., Puente N., et al. Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription. Exp. Hematol. 2010, 38(3):233-245.
68. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat. Rev. Cancer 2009, 9(1):40-55.
69. Gesierich S., Berezovskiy I., Ryschich E., Zoller M. Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res. 2006, 66(14):7083-7094.
70. Millimaggi D., Mari M., D'Ascenzo S., Carosa E., Jannini E.A., Zucker S., et al. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 2007, 9(4):349-357.
71. Al-Nedawi K., Meehan B., Kerbel R.S., Allison A.C., Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci USA 2009, 106(10):3794-3799.
72. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10(12):1470-1476.
73. Webber J., Steadman R., Mason M.D., Tabi Z., Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010, 70(23):9621-9630.
74. Castellana D., Zobairi F., Martinez M.C., Panaro M.A., Mitolo V., Freyssinet J.M., et al. Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: a role for activated fibroblasts and CX3CL1-CX3CR1 axis. Cancer Res. 2009, 69(3):785-793.
75. Sun J., Hemler M.E. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res. 2001, 61(5):2276-2281.
76. Wysoczynski M., Ratajczak M.Z. Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int. J. Cancer 2009, 125(7):1595-1603.
77. Huber V., Filipazzi P., Iero M., Fais S., Rivoltini L. More insights into the immunosuppressive potential of tumor exosomes. J Transl Med 2008, 6:63.
78. Andreola G., Rivoltini L., Castelli C., Huber V., Perego P., Deho P., et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 2002, 195(10):1303-1316.
79. Huber V., Fais S., Iero M., Lugini L., Canese P., Squarcina P., et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005, 128(7):1796-1804.
80. Kim J.W., Wieckowski E., Taylor D.D., Reichert T.E., Watkins S., Whiteside T.L. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 2005, 11(3):1010-1020.
81. Aliotta J.M., Sanchez-Guijo F.M., Dooner G.J., Johnson K.W., Dooner M.S., Greer K.A., et al. Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation. Stem Cells 2007, 25(9):2245-2256.
82. Al-Nedawi K., Meehan B., Micallef J., Lhotak V., May L., Guha A., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 2008, 10(5):619-624.
83. Goldenberg D.M., Pavia R.A. Horizontal transmission of malignant conditions rediscovered. N. Engl. J. Med. 1981, 305(5):283-284.
84. Bergsmedh A., Szeles A., Henriksson M., Bratt A., Folkman M.J. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci USA 2001, 98(11):6407-6411.
85. Vlassov V.V., Laktionov P.P., Rykova E.Y. Circulating nucleic acids as a potential source for cancer biomarkers. Curr. Mol. Med. 2010, 10(2):142-165.
86. Urbanova M., Plzak J., Strnad H., Betka J. Circulating nucleic acids as a new diagnostic tool. Cell. Mol. Biol. Lett. 2010, 15(2):242-259.
87. Jung T., Castellana D., Klingbeil P., Cuesta Hernandez I., Vitacolonna M., Orlicky D.J., et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 2009, 11(10):1093-1105.
88. Lima L.G., Chammas R., Monteiro R.Q., Moreira M.E., Barcinski M.A. Tumor-derived microvesicles modulate the establishment of metastatic melanoma in a phosphatidylserine-dependent manner. Cancer Lett. 2009, 283(2):168-175.